The Psychedelics Newsletter

Psychedelic profiles: Psilocybin, Partnership places London at the heart of psychedelic research, The parliamentary debate to reschedule psilocybin.

Psychedelic profiles: MDMA, Oregon licenses first centre to provide psilocybin services, Ketamine therapy for mental health conditions.

Accessing psilocybin in the UK, Microdosing linked to improved brain function, American Medical Association issues code for psychedelics.

PSYCH Symposium returns to London, Inside the UK-funded ketamine study, American Pharmacists Association supports drug decriminalisation.

The 80th birthday of LSD, Oregon licenses first psilocybin facilitators, Awakn partners with the University of Exeter.

The rise in psychedelic research, Accessing psychedelic medicine in Europe, MAPS announce Phase III study data.

The value of patents in psychedelic medicine, First facilitators of psilocybin services graduate in Oregon, Small Pharma releases data from Phase II DMT study.

The CURE Act in Illinois, Supporting psychedelic medicine in Europe, Oregon issues first psilocybin licence.

Beckley Psytech’s IV psilocin formulation, UK announces new drug authorisation model, DMT neuroimaging study conducted.

Psilocybin therapy for methamphetamine and opioid use disorders, Psychedelic medicines in women's health, Cybin's drug development pipeline.

The cost-benefit of MDMA-assisted therapy, quantitative data in psychedelic therapy, European regulators urged to reschedule psychedelic medicine

Psychedelic-assisted therapy for harmful gambling, EU regulators promote psychedelic medicine, PAREA campaigns for psychedelic healthcare in Europe.